# Who does Regeneron Pharmaceuticals pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/regeneron-pharmaceuticals · Facet: suppliers · Updated: 2026-10-11T20:28:40.036+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Regeneron Pharmaceuticals's confirmed suppliers/cost counterparties include Alnylam Pharmaceuticals, Bristol-Myers Squibb Company, Fujifilm Holdings. Per the valuechain.wiki graph: 3 cost edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-10-11).

### 앨라일람 (high)  → /alnylam-pharmaceuticals.md
- metric: Amount $100M · FY2023 · Development milestone recognized as acquired IPR&D expense under the Alnylam collaboration
- note: Regeneron funds programs and pays milestones to Alnylam under their RNAi collaboration covering ocular, central nervous system and liver targets. It recognized a development milestone payment in 2023.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-04) https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm: "$100.0 million development milestone"

### 브리스톨 마이어스 스퀴브 (high)  → /bristol-myers-squibb.md
- note: Regeneron and Sanofi licensed patents needed to develop and sell Libtayo from Bristol-Myers Squibb entities and Ono Pharmaceutical. Regeneron pays royalties to the licensor group, but the portion attributable specifically to Bristol-Myers Squibb is not disclosed.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-04) https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm: "royalties of 2.5%"

### 테세라 테라퓨틱스 (high)
- note: Regeneron purchased Tessera Therapeutics preferred stock after their TSRA-196 collaboration became effective. The amount allocated to the preferred-stock purchase was not disclosed separately from the licensing upfront payment.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-04) https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm: "purchase of Tessera preferred stock"

### 후지필름홀딩스 (high)  → /fujifilm-holdings.md
- note: Regeneron entered into a 10-year, $3B+ U.S. manufacturing agreement with Fujifilm Holdings subsidiary Diosynth to produce antibodies at the new Holly Springs plant ($3.2B), making it the anchor deal for Healthcare bio-CDMO growth.
- [confirms] FUJIFILM Diosynth Biotechnologies (EN, ir, published 2025-04-22) https://www.fujifilm.com/us/en/news/biotechnology/fujifilm-diosynth-biotechnologies-and-regeneron-sign-a-10-year-us-manufacturing-agreement-valued-at-over-3-billion: "FUJIFILM Diosynth Biotechnologies and Regeneron signed a 10-year U.S. manufacturing agreement valued at over $3 billion, with production at the Holly Springs large-scale facility."
- [confirms] Pharm Edaily (KO, news, published 2024-11-08) https://pharm.edaily.co.kr/news/read?newsId=01918806638856120: "Fujifilm invests an additional ~JPY180B (KRW1.6T) to expand its North Carolina bio-CDMO plant, adding antibody capacity."

Reverse side: https://valuechain.wiki/regeneron-pharmaceuticals/customers.md · Ripple: https://valuechain.wiki/regeneron-pharmaceuticals/ripple.md

---
Full node: https://valuechain.wiki/regeneron-pharmaceuticals.md · JSON: https://valuechain.wiki/regeneron-pharmaceuticals.json